30.5.2024
29.5.2024
27
May
2024
4
Jun
5
Find more news and events
Suomeksi
In English
A new study from the University of Eastern Finland and the University of Tübingen helps to explain what defines how long a drug molecule stays bound to its target.
One of the most comprehensive ocular pharmacokinetic studies including metabolism so far provides valuable information for ocular drug development.
Regular physical activity significantly changes the body’s metabolite profile, and many of these changes are associated with a lower risk of type 2 diabetes, a new study shows.
Most of the disease-modifying antirheumatic drugs were not associated with the risk of Parkinson's disease, a new register-based study shows. An exception was the use of chloroquine or hydroxychloroquine which associated with a lower risk.
Experiences of people with dementia and their family members show researchers how a progressive illness affects the realisation of the fundamental rights, and how the status of people with dementia can be improved.
Arterial stiffness may be a novel risk factor to be targeted in the prevention and treatment of insulin resistance and dyslipidaemia from a young age, a new study suggests.
“Coronary artery disease has, for a long time, been mainly treated with cholesterol-lowering drugs, but there is a need for other types of treatments as well. For example, new drugs could target pathogenic changes taking place in the arterial wall,” Professor Minna Kaikkonen-Määttä says.
The results suggest that vitamin D3 supplementation may have an important role in preventing infectious diseases or reducing their severe consequences.
The FIND trial found that taking a much higher dose of vitamin D than recommended for five years did not affect total mortality or the incidence of cardiovascular disease or cancer in older men and women.